Biaryl and heteroaryl derivatives of SCH 58261 as potent and selective adenosine A2A receptor antagonists

被引：19

作者：

Shah, Unmesh ^{[1
]}

Boyle, Craig D. ^{[1
]}

Chackalamannil, Samuel ^{[1
]}

Neustadt, Bernard R. ^{[1
]}

Lindo, Neil ^{[1
]}

Greenlee, William J. ^{[1
]}

Foster, Carolyn ^{[1
]}

Arik, Leyla ^{[1
]}

Zhai, Ying ^{[1
]}

Ng, Kwokei ^{[1
]}

Wang, Shiyong ^{[1
]}

Monopoli, Angela ^{[1
]}

Lachowicz, Jean E. ^{[1
]}

机构：

[1] Schering Plough Corp, Res Inst, Kenilworth, NJ 07033 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2008年 / 18卷 / 14期

关键词：

adenosine; A(2A); A(2A) receptor; A(2A) antagonist; A(2A) receptor antagonist; SCH; 58261; Parkinson's Disease;

D O I：

10.1016/j.bmcl.2008.05.074

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

SCH 58261 is a reported adenosine A(2A) receptor antagonist, which is active in rat in vivo models of Parkinson's Disease upon ip administration. However, it has poor selectivity versus the A(1) receptor and does not demonstrate oral activity. We report the design and synthesis of biaryl and heteroaryl analogs of SCH 58261 which improve the A(2A) receptor binding selectivity as well as the pharmacokinetic properties of SCH 58261. In particular, the quinoline 25 has excellent A(2A) receptor in vitro binding affinity and selectivity, sustained rat plasma levels upon oral dosing, and is active orally in a rat behavioral assay. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：4199 / 4203

页数：5

共 16 条

[1] ADENOSINE A(2A) RECEPTOR MESSENGER-RNA IS EXPRESSED BY ENKEPHALIN CELLS BUT NOT BY SOMATOSTATIN CELLS IN RAT STRIATUM - A COEXPRESSION STUDY [J].

AUGOOD, SJ ;

EMSON, PC .

MOLECULAR BRAIN RESEARCH, 1994, 22 (1-4) :204-210

[2] Adenosine A2A receptor antagonist treatment of Parkinson's disease [J].

Bara-Jimenez, W ;

Sherzai, A ;

Dimitrova, T ;

Favit, A ;

Bibbiani, F ;

Gillespie, M ;

Morris, MJ ;

Mouradian, MM ;

Chase, TN .

NEUROLOGY, 2003, 61 (03) :293-296

[3] Novel in vivo procedure for rapid pharmacokinetic screening of discovery compounds in rats [J].

Cox, KA ;

Dunn-Meynell, K ;

Korfmacher, WA ;

Broske, L ;

Nomeir, AA ;

Lin, CC ;

Cayen, MN ;

Barr, WH .

DRUG DISCOVERY TODAY, 1999, 4 (05) :232-237

[4] STIMULATION OF HIGH-AFFINITY ADENOSINE-A2 RECEPTORS DECREASES THE AFFINITY OF DOPAMINE D2 RECEPTORS IN RAT STRIATAL MEMBRANES [J].

FERRE, S ;

VONEULER, G ;

JOHANSSON, B ;

FREDHOLM, BB ;

FUXE, K .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (16) :7238-7241

[5] STRUCTURE ACTIVITY PROFILE OF A SERIES OF NOVEL TRIAZOLOQUINAZOLINE ADENOSINE ANTAGONISTS [J].

FRANCIS, JE ;

CASH, WD ;

PSYCHOYOS, S ;

GHAI, G ;

WENK, P ;

FRIEDMANN, RC ;

ATKINS, C ;

WARREN, V ;

FURNESS, P ;

HYUN, JL ;

STONE, GA ;

DESAI, M ;

WILLIAMS, M .

JOURNAL OF MEDICINAL CHEMISTRY, 1988, 31 (05) :1014-1020

[6]

FREDHOLM BB, 1994, PHARMACOL REV, V46, P143

[7] Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD [J].

Hauser, RA ;

Hubble, JP ;

Truong, DD .

NEUROLOGY, 2003, 61 (03) :297-303

[8] Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings (Reprinted from Advanced Drug Delivery Reviews, vol 23, pg 3-25, 1997) [J].

Lipinski, CA ;

Lombardo, F ;

Dominy, BW ;

Feeney, PJ .

ADVANCED DRUG DELIVERY REVIEWS, 2001, 46 (1-3) :3-26

[9] Adenosine A(2) receptors modulate haloperidol-induced catalepsy in rats [J].

Mandhane, SN ;

Chopde, CT ;

Ghosh, AK .

EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 328 (2-3) :135-141

[10] 2-(2-furanyl)-7-phenyl[1,2,4]triazolo[1,5-c]pyrimidin-5-amine analogs:: Highly potent, orally active, adenosine A2A antagonists.: Part 1 [J].

Matasi, JJ ;

Caldwell, JP ;

Zhang, HT ;

Fawzi, A ;

Cohen-Williams, ME ;

Varty, GB ;

Tulshian, DB .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (16) :3670-3674

← 1 2 →